Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE7A | Q13946 | 5/20 | 0.73 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.63 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30837926 | 1.00 | PDE7A (0.73) | PDE7APDE7BHTTCA12CA1 | |
| SCHEMBL3341796 | 0.85 | ALDH1A1 (0.66) | PDE7APDE7BHTTCA12CA1 | |
| SCHEMBL299166 | 0.84 | PDE7A (1.00) | PDE7APDE7BHTTCA12CA1 | |
| SCHEMBL30837953 | 0.84 | PDE7A (1.00) | PDE7APDE7BHTTCA12CA1 | |
| SCHEMBL9953998 | 0.82 | CA12 (0.58) | PDE7APDE7BHTTCA12CA1 | |
| SCHEMBL18239987 | 0.79 | PDE7A (0.77) | PDE7APDE7BHTTCA12CA1 | |
| SCHEMBL31419817 | 0.79 | PDE7A (0.77) | PDE7APDE7BHTTCA12CA1 | |
| SCHEMBL18239982 | 0.78 | PDE7A (1.00) | PDE7ACA12CA1CA2CA9 | |
| SCHEMBL30837960 | 0.78 | PDE7A (1.00) | PDE7APDE7BCA12CA1CA2 | |
| SCHEMBL6283951 | 0.78 | PDE7A (0.71) | PDE7APDE7BHTTCA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9192610-B2 | Use of quinazoline derivatives for neurodegenerative diseases | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2015-11-24 | — | — | US | claimed |
| EP-2433637-B9 | USE OF QUINAZOLINE DERIVATIVES FOR NEURODEGENERATIVE DISEASES | CONSEJO SUPERIOR INVESTIGACION (ES) | 2015-06-10 | — | — | EP | claimed |
| EP-2433637-B1 | USE OF QUINAZOLINE DERIVATIVES FOR NEURODEGENERATIVE DISEASES | CONSEJO SUPERIOR INVESTIGACION (ES) | 2014-06-11 | — | — | EP | claimed |
| US-20120129877-A1 | USE OF QUINAZOLINE DERIVATIVES FOR NEURODEGENERATIVE DISEASES | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2012-05-24 | — | — | US | claimed |
| EP-2433637-A1 | USE OF QUINAZOLINE DERIVATIVES FOR NEURODEGENERATIVE DISEASES | Consejo Superior de Investigaciones Científicas (CSIC) (ES) | 2012-03-28 | — | — | EP | claimed |
| US-20260060970-A1 | Use of a Therapeutic Agent with Phosphodiesterase-7 Inhibitory Activity for the Treatment and Prevention of Diseases Associated with Chronic Fatigue, Exhaustion and/or Exertional Intolerance | MITODICURE GMBH (DE) | 2026-03-05 | — | — | US | disclosed |
| US-9796687-B2 | S-substituted quinazolines and their therapeutic applications for the treatment of diseases mediated by PDE7 | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2017-10-24 | — | — | US | disclosed |
| US-20160340320-A1 | S-SUBSTITUTED QUINAZOLINES AND THEIR THERAPEUTIC APPLICATIONS FOR THE TREATMENT OF DISEASES MEDIATED BY PDE7 | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2016-11-24 | — | — | US | disclosed |
| EP-3095446-A1 | S-SUBSTITUTED QUINAZOLINES AND THEIR THERAPEUTIC APPLICATIONS FOR THE TREATMENT OF DISEASES MEDIATED BY PDE7 | Consejo Superior de Investigaciones Cientificas (CSIC) (ES) | 2016-11-23 | — | — | EP | disclosed |
| US-9192610-B2 | Use of quinazoline derivatives for neurodegenerative diseases | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2015-11-24 | — | — | US | disclosed |
| EP-2433637-B9 | USE OF QUINAZOLINE DERIVATIVES FOR NEURODEGENERATIVE DISEASES | CONSEJO SUPERIOR INVESTIGACION (ES) | 2015-06-10 | — | — | EP | disclosed |
| EP-2433637-B1 | USE OF QUINAZOLINE DERIVATIVES FOR NEURODEGENERATIVE DISEASES | CONSEJO SUPERIOR INVESTIGACION (ES) | 2014-06-11 | — | — | EP | disclosed |
| US-20120129877-A1 | USE OF QUINAZOLINE DERIVATIVES FOR NEURODEGENERATIVE DISEASES | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2012-05-24 | — | — | US | disclosed |
| EP-2433637-A1 | USE OF QUINAZOLINE DERIVATIVES FOR NEURODEGENERATIVE DISEASES | Consejo Superior de Investigaciones Científicas (CSIC) (ES) | 2012-03-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260060970-A1 | Use of a Therapeutic Agent with Phosphodiesterase-7 Inhibitory Activity for the Treatment and Prevention of Diseases Associated with Chronic Fatigue, Exhaustion and/or Exertional Intolerance | PDE5A, PDE4C, PDE12 | PDE7A 5/4885PDE7B 14/4885HTT 2169/4885 |
| US-20160340320-A1 | S-SUBSTITUTED QUINAZOLINES AND THEIR THERAPEUTIC APPLICATIONS FOR THE TREATMENT OF DISEASES MEDIATED BY PDE7 | PDE7B, PDE7A, PDE4A | PDE7A 2/4885PDE7B 1/4885HTT 1311/4885 |
| US-20120129877-A1 | USE OF QUINAZOLINE DERIVATIVES FOR NEURODEGENERATIVE DISEASES | PARK7, SNCA, NLN | PDE7A 867/4885PDE7B 409/4885HTT 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.